Abstract: The present invention relates to humanized antibodies against SIRP? that are suitable for use in anti-cancer therapy. The invention further relates to the use of the humanized anti-SIRP? antibodies in the treatment of human solid tumours and haematological malignancies, optionally in combination with further anti-cancer therapeutics.

Abstract: Duocarmycin-based antibody-drug conjugates can be readily separated from non-conjugated duocarmycin linker-drug in a composition that contains a solvent system of water and acetonitrile and that has 30% to 60% acetonitrile.

Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.

Abstract: The invention relates to antibodies against SIRP? that are suitable for use in anti-cancer therapy. The invention also relates to the use of the anti-SIRP? antibodies in the treatment of human solid tumours and haematological malignancies, optionally in combination with other anti-cancer therapies.

Abstract: The present invention relates to a process for preparing antibody-drug conjugates and to antibody-drug conjugates wherein therapeutic moieties are conjugated to one or more engineered cysteines as well as to one or more reduced interchain cysteines via a cleavable or non-cleavable linker.

Abstract: The compound of formula (II) is an advantageous intermediate for improving the process of synthesizing the linker-drug vc-seco-DUBA, as well as for the overall process for preparing an antibody-drug conjugate comprising the vc-seco-DUBA linker-drug. The methods of making the compound of formula (II) can include recovery of the compound as a solid, such as via crystallization, in high yields and purity.

Abstract: The present invention relates to antibodies against the human 5T4 oncofoetal antigen and corresponding antibody-drug conjugates that are suitable for testing in clinical trials. The antibodies are cross-reactive for humans and cynomolgus monkeys and exhibit an affinity for human 5T4 antigen which is in the same order of magnitude as their affinity for cynomolgus monkey 5T4 antigen. The invention further relates to the use of the antibodies and corresponding ADCs in the treatment of solid tumours and haematological malignancies.

Abstract: The present invention relates to linker-drug compounds (LDs) and antibody-drug conjugates (ADCs) comprising a non-linear self-immolative linker, which is cleavable or transformable under appropriate conditions and which reduces the hydrophobicity of the antibody-drug conjugate.

Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).

Abstract: The present invention relates to antibodies against SIRP? that are suitable for use in anti-cancer therapy. The invention further relates to the use of the anti-SIRP? antibodies in the treatment of human solid tumours and haematological malignancies, optionally in combination with other anti-cancer therapeutics. The anti-SIRPalpha antibodies described are more specific than known anti-SIRPalpha antibodies, whereas they show excellent affinity for both SIRPalpha1 and SIRPalphaBIT. In one embodiment the anti-SIRPalpha antibodies do not bind to SIRPgamma. In a second embodiment, the anti-SIRPalpha antibodies do not bind to SIRPgamma and do not bind to SIRPbeta1v1. In a third embodiment, the anti-SIRPalpha antibodies do not bind to SIRPgamma and do not bind to SIRPeta1v2. In a fourth embodiment, the anti-SIRPalpha antibodies do not bind to SIRPbeta1v1.

Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.

Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.

Abstract: The present invention relates to lyophilized compositions comprising antibody-duocarmycin drug conjugates.

Abstract: The present disclosure relates to CDR defined antibodies targeting the 5T4 oncofoetal antigen (TPBG, 5T4, Wnt Activated Inhibitory Factor 1, WAIF1) which exhibit a binding affinity for human 5T4 antigen which is in the same order of magnitude as their affinity for cynomolgus monkey 5T4. Antibody-drug conjugates (ADCs), and their use in the treatment of human solid tumours and haematological malignancies are claimed.

Abstract: The present invention relates to the duocarmycin-containing antibody-drug conjugate (ADC) trastuzumab vc-seco-DUBA (SYD985) for use in the treatment of trastuzumab emtansine (T-DM1) refractory HER2 IHC 3+ or HER2 IHC 2+/FISH positive cancer patients, particularly T-DM1 refractory breast cancer patients.

Abstract: The present invention relates to a process for the selective reduction of cysteine-engineered antibodies comprising reacting an antibody comprising one or more engineered cysteines at positions selected from HC40, HC41,HC42, HC89, HC152, HC153, HC155, HC171, LC40, LC41, LC165, and LC168 with a compound according to formula (I), (II), (III), (IV), (V), (VI) or (VII): (I) (II) (III) (IV) (V) (VI) (VII), and to a process for the preparation of antibody conjugates, including antibody-drug conjugates (ADCs).

Abstract: The present invention relates to a process for the synthesis of mono-protected ?,?-diamino alkanes, the use of said process in a process for the synthesis of a linker drug comprising an ?,?-diamino alkane moiety and the use of the process of the present invention in a process for preparing an antibody-drug conjugate comprising an ?,?-diamino alkane moiety.